Millie Das

Medical oncologist, Thoracic specialist

Clinical Assistant Professor, Medicine - Oncology

Thoracic Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: Stanford University Hospital -Internal Medicine Residency Training Program (2007) CA

Internship: Stanford University Hospital -Internal Medicine Residency Training Program (2005) CA

Board Certification: Medical Oncology, American Board of Internal Medicine (2011)

Fellowship: Stanford University School of Medicine (2011) CA

Board Certification: Internal Medicine, American Board of Internal Medicine (2007)

Medical Education: University of Massachusetts Medical Center (2004) MA

Administrative Appointments

Staff Physician, VA Palo Alto Health Care System, 2011

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., & Wakelee, H. A. (2013). A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements. Clinical lung cancer, 14(5), 592-595.

A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17-E18.

Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study
Das, M., & Wakelee, H. (2012). Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study. JOURNAL OF THORACIC DISEASE, 4(6), 558-561.

Angiogenesis inhibitors.
Das, M., & Wakelee, H. (2012). Angiogenesis inhibitors. Journal of thoracic oncology , 7(16), S397-8.

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., & Bruce, R. H. (2012). ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung cancer , 77(2), 421-426.

Angiogenesis Inhibitors
Das, M., & Wakelee, H. (2011). Angiogenesis Inhibitors. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1801-S1802.

Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer
Das, M., Donington, J. S., Murphy, J., Kozak, M., Eclov, N., & Wakelee, H. (2011). Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 12(5), 280-285.

Vascular Disrupting Agents
Das, M., & Wakelee, H. (2010). Vascular Disrupting Agents. JOURNAL OF THORACIC ONCOLOGY, 5(12), S482-S483.

Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?
Das, M., Abdelmaksoud, M. Hk., Loo, B. W., & Kothary, N. (2010). Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 11(1-2), 24-35.